trans-5-chloro-N-[4-(3-ethyl-2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-cyclohexyl]-2-methyl-nicotinamide | 1319742-74-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: trans-5-chloro-N-[4-(3-ethyl-2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-cyclohexyl]-2-methyl-nicotinamide
• CAS: 1319742-74-9
• 化学式: C₂₃H₂₇ClN₄O₂
• 分子量: 426.946
• InChiKey: FFMNQLRIMQJKNK-SAABIXHNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.17
• 重原子数：
  30.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  68.92
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  1-N-乙基苯-1,2-二胺 在 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 3.67h， 生成 trans-5-chloro-N-[4-(3-ethyl-2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-cyclohexyl]-2-methyl-nicotinamide
  参考文献：
  名称：

  [EN] CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS
  [FR] DÉRIVÉS DE CYCLOHEXYLAMIDE UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DU CRF

  摘要：

  公开号：

  WO2011092293A3

文献信息

• CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS
  申请人：Atkinson Benjamin

  公开号：US20110201629A1

  公开（公告）日：2011-08-18

  There are described cyclohexyl amide derivatives of Formula I, which are useful as corticotropin releasing factor (CRF) receptor antagonists and as pharmaceuticals.

  描述了一种公式I的环己基酰胺衍生物，其作为促肾上腺皮质激素释放因子（CRF）受体拮抗剂和药物是有用的。
• Method for preventing or treating heart failure by administering a medicament containing an antagonist of corticotropin releasing hormone receptor 2 (CRHR2)
  申请人：RAQUALIA PHARMA INC.

  公开号：US11135270B2

  公开（公告）日：2021-10-05

  A medicament for preventing or treating heart failure containing an antagonist of the corticotropin releasing hormone receptor 2 as an active ingredient.

  一种用于预防或治疗心力衰竭的药物，其活性成分中含有促肾上腺皮质激素释放激素受体 2 的拮抗剂。
• MEDICAMENT FOR PREVENTING OR TREATING HEART FAILURE
  申请人：NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY

  公开号：US20190160151A1

  公开（公告）日：2019-05-30

  A medicament for preventing or treating heart failure containing an antagonist of the corticotropin releasing hormone receptor 2 as an active ingredient.
• FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST
  申请人：RaQualia Pharma Inc.

  公开号：US20210078975A1

  公开（公告）日：2021-03-18

  The present invention relates to fused cyclic urea derivatives which have antagonistic activities against CRHR1 and/or CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR1 and/or CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR1 and/or CRHR2 is involved.
• METHOD FOR PREVENTING OR TREATING HEART FAILURE BY ADMINISTERING A MEDICAMENT CONTAINING AN ANTAGONIST OF CORTICOTROPIN RELEASING HORMONE RECEPTOR 2 (CRHR2)
  申请人：RaQualia Pharma Inc.

  公开号：US20210379158A1

  公开（公告）日：2021-12-09

  A medicament for preventing or treating heart failure containing an antagonist of the corticotropin releasing hormone receptor 2 as an active ingredient.